Trial | Number of subjects | Gestational age at randomization (weeks) | Magnesium sulfate dose | Death | Cerebral palsy | Composite outcome | Other outcomes |
ACTOMgSO4 | 1062 | <30 | 4 g loading dose followed by 1 g/hour for maximum of 24 hours | Total pediatric mortality:
| Cerebral palsy:
| Death or cerebral palsy:
| Substantial gross motor dysfunction:
Death or substantial gross motor dysfunction:
|
BEAM | 2241 | 24 to 31 | 6 g loading dose followed by 2 g/hour for maximum of 12 hours | Death:
| Moderate to severe cerebral palsy:
| Stillbirth or infant death by one year of corrected age or moderate or severe cerebral palsy at or beyond two years of corrected age:
| |
PREMAG | 573 | <33 | 4 g loading dose, no maintenance dose | Cerebral palsy or death:
Severe motor dysfunction or death:
| |||
MAGENTA | 1433 | 30 to <32 32 to <34 | 4 g loading dose, no maintenance dose | Death of liveborn infant before hospital discharge:
| Cerebral palsy:
| Death or cerebral palsy:
|
ACTOMgSO4: Australasian Collaborative Trial of Magnesium Sulphate; BEAM: Beneficial Effects of Antenatal Magnesium Sulfate; MAGENTA: Magnesium Sulphate at 30 to 34 Weeks' Gestational Age; OR: odds ratio; RR: relative risk.
* When evaluated in terms of gestational age at randomization (<28 weeks versus ≥28 weeks), only infants of pregnancies randomized at <28 weeks had a significant reduction in moderate or severe cerebral palsy.Do you want to add Medilib to your home screen?